Improving the interpretation of MRI will allow more timely and effective diagnosis of metastatic prostate cancer in settings that lack PSMA PET imaging, and it will greatly benefit patients by allowing them to receive earlier treatment. Here, FOLH1 is linked to metastatic prostate carcinoma.